Printer Friendly Version View printer-friendly version
<< Back
Mediclinic Intnl plc - Directorate Change
RNS Number : 6211X
Mediclinic International plc
27 November 2017
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic" or "the Company")

 

THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION

 

 

27 November 2017

 

 

 

APPOINTMENT OF GROUP CHIEF EXECUTIVE OFFICER

 

 

Mediclinic International plc announces the appointment of Dr Carel Aron (Ronnie) van der Merwe, currently Mediclinic's Group Chief Clinical Officer, as Chief Executive Officer ("CEO") Designate to succeed Danie Meintjes as CEO of the Company on a date to be mutually agreed, but not later than 1 August 2018. This follows the announcement made on 25 July 2017 that Mr Meintjes will retire from his position as Chief Executive Officer and a director of the Company by no later than 31 July 2018.

 

Dr Van der Merwe joined Mediclinic in 1999 and has been a member of the Group's Executive Committee since 2008. He established the Clinical Information, Advanced Analytics, Health Information Management and Clinical Services functions at Mediclinic and has been Group Chief Clinical Officer since 2007. He was appointed as a director of Mediclinic International Limited in 2010 up to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited. He is also a member of the Board of Directors at Wits Donald Gordon Medical Centre (Pty) Ltd and is the Chairman of the Board of Trustees for the Remedi Medical Aid Scheme.

 

Dr Van der Merwe obtained qualifications in Advanced Management (Harvard Business School, USA), a Fellowship in Anaesthesia (College of Anaesthesiologists, South Africa) where he was the recipient of the Jack Abelsohn Medal and a Bachelor of Medicine and Bachelor of Surgery (University of Stellenbosch, South Africa).

 

Dr Edwin Hertzog, Chairman of Mediclinic, commented: "Danie has been instrumental to the development of Mediclinic into a respected international healthcare provider delivering high-quality, cost-efficient services to patients. We look forward to continuing to work with him until his retirement. We are delighted that Ronnie van der Merwe will succeed Danie in leading Mediclinic, following the thorough and rigorous global selection process carried out by the Nomination Committee with the support from the other Non-Executive Directors. The Committee and the Board were unanimous in their support for Ronnie, given his extensive knowledge of Mediclinic's international operations and strong track record of driving enhancements especially in the quality and effectiveness of our clinical services."

 

Danie Meintjes said: "It has been a great privilege to lead Mediclinic's business since 2010 and be part of its development for more than three decades. The Company is in a strong position with good prospects for growth and I am pleased that I will be leaving it in the capable hands of Ronnie van der Merwe, supported by the senior management team."

 

Dr Van der Merwe said: "I am delighted to have been asked by the Board to take over as Mediclinic's next CEO. I look forward to working with Danie and all Mediclinic colleagues, clinicians, customers, shareholders and other stakeholders, to ensure a smooth handover and address the challenges and opportunities facing our business in the near, medium and long term."

 

There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.

 

 

Additional information

 

As CEO of Mediclinic, Dr Van der Merwe will receive an annual salary and board fees amounting to £520,367* and he will also be eligible to participate in the Company's short term incentive scheme ("STI") and long term incentive plan ("LTIP"), designed to incentivise and reward the successful delivery of the business strategy and sustained shareholders value creation. Dr Van der Merwe's maximum award opportunity under the STI will be 150% of his annual salary, half of which will be subject to a compulsory deferral for a period of two years. Awards under the LTIP are up to a maximum value of 200% of annual salary, with vesting subject to performance over a three year period and an additional two-year holding period required following vesting and prior to their release. In accordance with best practice both the bonus and LTIP contains provisions that will allow the Company to recover or withhold value in the event of certain defined circumstances. Dr Van der Merwe's service agreement may be terminated on six months' notice by either side.

 

Dr Van der Merwe holds 30,630 shares in the Company and will be expected to build and maintain his shareholding in the Company to the value of 225% of his annual base salary and retain no less than 50% of the net share releases from his deferred bonus and LTIP awards until this requirement is met.

 

The above remuneration package and arrangements match those of the departing CEO, Danie Meintjes, and are consistent with the terms of the Directors' Remuneration Policy approved by shareholders at the Annual General Meeting held in July 2017.

 

*      The GBP cash equivalent has been calculated using the following exchange rate: £1: ZAR 18.52, being the 5-day average GBP/ ZAR exchange rate on Friday, 24 November 2017 at 3:00pm GMT Bloomberg.

 

 

About Mediclinic International plc

 

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

 

Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

 

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Victoria Dalby / Caroline Emmet

+44 (0)20 7954 9600

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com  

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard / Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, United Kingdom, EC2V 7NQ  

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGBWGUPMGWM

IMPORTANT DISCLAIMER

ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS, RULES OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT OR PHYSICALLY PRESENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY, OR DISTRIBUTED OR DISSEMINATED TO, DIRECTLY OR INDIRECTLY, PERSONS RESIDENT OR PHYSICALLY LOCATED IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS, RULES OR REGULATIONS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH CONSENT OR OTHER FORMALITY WHICH MEDICLINIC REGARDS AS UNDULY ONEROUS.

Combination of Mediclinic International Limited ("Mediclinic") and Al Noor Hospitals Group plc ("Al Noor") (the "Combination")

Access to the website

You are attempting to enter the part of the website that is designated for the publication of documents and information in connection with the Combination.

If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. Mediclinic reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of Mediclinic.

This part of the website contains electronic versions of materials relating to the Combination. The materials you are seeking to access are made available in good faith and for information purposes only and are subject to the terms and conditions set out below. Any person seeking to access this part of the website represents and warrants to Mediclinic that they are doing so for information purposes only.

To allow you to view information about the Combination, you must read this notice and then click "I ACCEPT". If you are unable to agree, you should click "I DECLINE" and you will not be able to view information about the Combination.

The Combination would be made by means of a scheme document to be published by Mediclinic which would contain the full terms and conditions of such Combination, including details on how it may be accepted. Any decision made in relation to the Combination should be made solely and only on the basis of the information provided in any such document.

Overseas jurisdictions

Viewing the materials you are seeking to access may be restricted under securities laws in certain jurisdictions. All persons who wish to view this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.

These materials are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS PART OF THE WEBSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO. MEDICLINIC AND ITS ADVISERS DO NOT ASSUME ANY LIABILITY FOR ANY VIOLATION BY ANY PERSON OF ANY OF THESE RESTRICTIONS.

It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should click on “I DECLINE” below and exit this webpage.

Cautionary Note Regarding Forward-Looking Statements

This part of the website and the information contained in it may contain certain forward-looking statements with respect to the financial condition, results of operations and businesses of Mediclinic and the Mediclinic Group (being Mediclinic and its subsidiaries and subsidiary undertakings) and Al Noor and the Al Noor Group (being Al Noor and its subsidiaries and subsidiary undertakings) following the Combination. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic and the Mediclinic Group to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases. There are a number of factors that could affect the future operations of Mediclinic and the Mediclinic Group and Al Noor and the Al Noor Group post Combination and could cause those results to differ materially from those expressed in the forward-looking statements included in this part of the website. All forward-looking statements contained in this part of the website are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as at the specified date of the relevant document within which the statement is contained. None of Mediclinic, the Mediclinic Group, Al Noor or the Al Noor Group undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this part of the website.

Responsibility

In relation to any Combination-related materials accessible on this area of the website please note any statement of responsibility contained therein.

The documents included in this part of the website issued or published by Mediclinic speak only at the specified date of the relevant document and Mediclinic has, and accepts, no responsibility or duty to update or revise such documents.

In relation to any such announcements or other Combination-related materials issued or published by Al Noor, or which relate to Al Noor and the Al Noor Group, that are accessible on this website, the only responsibility accepted by Mediclinic and its directors is for the correctness and fairness of its reproduction.

Neither the directors of Mediclinic, nor Mediclinic, nor any of their affiliated companies, have reviewed, and no such person is or shall be responsible for or accepts any liability in respect of, any information contained on any other website which may be linked to or from this part of the website.

Other

If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an appropriately authorised independent financial adviser.

This notice shall be governed by and construed in accordance with English law.

CONFIRMATION OF UNDERSTANDING AND ACCEPTANCE

If you are not able to give these confirmations, you should click on “I DECLINE” below and exit the webpage.